EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative evaluation of TRIDs : a strategy to improve treatments

Fatima Hariss, Sacha Spelier, Louise Damy, Carmen Sandoval Pacheco, Luca Houpe, Catherine Leroy, Xavier Thuru, Frédéric Becq, Fabrice Lejeune iD

Journal of Translational Medicine · 31.03.2026 · 24 (1)

DOI: 10.1186/s12967-026-08058-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Translational Medicine, online erschienen am 31.03.2026. Verfasst von Fatima Hariss und 8 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, Inserm, CHU Lille, CNRS, U1366-UMR9020 - CRCLille - Cancer Research Center of Lille, Lille, F-59000, France. Hauptthemen laut MEDLINE: Protein Biosynthesis. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Translational readthrough represents a promising therapeutic strategy for genetic disorders caused by nonsense mutations. Although multiple translational readthrough-inducing drugs (TRIDs) have been reported, their relative efficacy remains inconsistent across studies, likely due to differences in experimental systems and cellular contexts. A systematic comparison across complementary and clinically relevant models is therefore required to better define their therapeutic potential. This study aims to evaluate and compare the efficiency of different TRIDs used for nonsense mutation correction.

Methods

We performed a comparative evaluation of 12 TRIDs using a panel of cellular models encompassing increasing levels of physiological relevance. These included a firefly luciferase-based reporter assay, human cell lines harboring endogenous TP53 nonsense mutations, patient-derived intestinal organoids carrying CFTR nonsense variants, and Fischer rat thyroid (FRT) cells expressing homozygous CFTR nonsense mutations. Readthrough efficiency was assessed and compared across models.

Results

Across the different systems, 2,6-diaminopurine (DAP), clitocine, SRI-41315, and TLN468 consistently exhibited the highest readthrough activity. However, variations in relative efficacy were observed depending on the assay and cellular context, underscoring the influence of experimental conditions, amino acid incorporation profiles, and cell-specific determinants on readthrough outcomes.

Conclusions

Our findings demonstrate the necessity of evaluating candidate TRIDs across multiple complementary and patient-relevant models to accurately estimate their therapeutic potential. This study identifies several promising compounds for further preclinical development and provides a comparative framework to guide the rational selection of readthrough-inducing agents for translational applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein BiosynthesisHumansAnimalsCodon, NonsenseCystic Fibrosis Transmembrane Conductance RegulatorRatsRats, Inbred F344Cell Line

Stichwörter der Autor:innen

Genetic diseasesNonsense mutationPremature termination codonSmall moleculesTranslational readthrough

Substanzen

Codon, NonsenseCystic Fibrosis Transmembrane Conductance Regulator

Autor:innen und Institutionen

  • Univ. Lille, Inserm, CHU Lille, CNRS, U1366-UMR9020 - CRCLille - Cancer Research Center of Lille, Lille, F-59000, France.
  • Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht, 3584 EA, The Netherlands.
  • Regenerative Medicine Utrecht, University Medical Center, Utrecht University, Utrecht, 3584 CT, The Netherlands.
  • Centre for Living Technologies, University Medical Center, Utrecht University, Utrecht, 3584 CT, The Netherlands.
  • Laboratoire de physiopathologie et régulation des transports ioniques, Pôle Biologie Santé, Université de Poitiers, Poitiers, 86073, France.
  • Univ. Lille, Inserm, CHU Lille, CNRS, U1366-UMR9020 - CRCLille - Cancer Research Center of Lille, Lille, F-59000, France. fabrice.lejeune@inserm.fr.

ORCID-Profile: Fabrice Lejeune

Zitieren

APA

Hariss, F., Spelier, S., Damy, L., Pacheco, C. S., Houpe, L., Leroy, C., Thuru, X., Becq, F., & Lejeune, F. (2026). Comparative evaluation of TRIDs : a strategy to improve treatments. Journal of Translational Medicine, 24(1). https://doi.org/10.1186/s12967-026-08058-5

Vancouver

Hariss F, Spelier S, Damy L, Pacheco CS, Houpe L, Leroy C, et al. Comparative evaluation of TRIDs : a strategy to improve treatments. Journal of Translational Medicine. 2026;24(1). doi:10.1186/s12967-026-08058-5

BibTeX
@article{Hariss2026,
  author = {Hariss, Fatima and Spelier, Sacha and Damy, Louise and Pacheco, Carmen Sandoval and Houpe, Luca and Leroy, Catherine and Thuru, Xavier and Becq, Frédéric and Lejeune, Fabrice},
  title = {Comparative evaluation of TRIDs : a strategy to improve treatments},
  journal = {Journal of Translational Medicine},
  year = {2026},
  volume = {24},
  number = {1},
  doi = {10.1186/s12967-026-08058-5}
}
Kostenlos starten →